|
Metropolis Healthcare, India’s second-largest diagnostic chain, has posted better financial performance during the second quarter ended September 2025 due to expansion and acquisition. The board of directors announced interim equity dividend of 200 per cent for the year 2024-25. Currently the Rs. 2 scrip is quoted around Rs. 2,031 on BSE with 52-weeks high at Rs. 2,259.
The revenue of Metropolis went up by 22.6 per cent to Rs. 429 crore during the second quarter ended September 2025 from Rs. 350 crore and its net profit increased by 12.8 per cent to Rs. 53 crore as against Rs. 47 crore in the last period. Its patient and test volumes grew 11 per cent and 12 per cent on YoY, respectively, with B2C and B2B revenues rising 16 per cent and 33 per cent. Revenue per Patient (RPP) and Revenue per Test (RPT) increased 11 per cent and 10 per cent, supported by brand trust, premium offerings, and rising demand for preventive and specialty testing. TruHealth wellness and Specialty portfolios recorded strong growth of over 24 per cent and 33 per cent YoY growth respectively, underscoring momentum in high-value services.
Despite lower seasonal illness incidence, performance remained strong, reflecting portfolio strength and growing demand for preventive health. B2B segment consistently delivered double-digit growth supported by report quality and service standards. Higher-end offerings in TruHealth and Genomics/AI testing in Specialty, accelerating strategic growth priorities.
Ameera Shah, promoter and executive chairperson, “We've demonstrated that consistent growth and quality can go hand in hand. The swift turnaround of Core Diagnostics and the strong performance of our recent acquisitions in Dehradun and Agra reaffirm the strength of our integration strategy and our ability to create sustainable value through local excellence. As we advance genomics and AI-enabled innovation alongside digital transformation, we’re driving rapid adoption that expands access to quality diagnostics and accelerates the sector’s shift from unorganised to organised players. Our focus remains on shaping a future-ready Metropolis — a trusted, science-led organisation that sets new benchmarks for quality, care, and value creation.”
For the first half ended September 2025, Metropolis recorded revenues of Rs. 815 crore as against Rs. 663 crore in the corresponding period of last year, registering a growth of 22.9 per cent. Its net profit increased to Rs. 98 crore from Rs. 85 crore in the last year. EPS worked out to Rs. 18.87 as compared to Rs. 16.49 in the last period. For the full year its revenues stood at Rs. 1,331 crore and net profit at Rs. 146 crore.
|